Katrin Rupalla
Direktor/Vorstandsmitglied bei 4D PHARMA PLC
Aktive Positionen von Katrin Rupalla
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
4D PHARMA PLC | Direktor/Vorstandsmitglied | 23.09.2020 | - |
Independent Dir/Board Member | 23.09.2020 | - | |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | General Counsel | - | - |
Ymmunobio AG
Ymmunobio AG BiotechnologyHealth Technology Ymmunobio AG is a Swiss preclinical stage oncology biotech company that develops innovative treatments for cancer patients through new classes of antibodies. The company is based in Riehen, Switzerland. The company focuses on high unmet need indications in gastro-intestinal cancers, making extensive progress in developing first-in-class or novel class of antibodies that have the potential to overcome resistance of cancer patients to current available therapies. Ymmunobio's research is based on their deep understanding of immuno-oncology and precision cancer treatments, leveraging their profound knowledge of biologics while selecting the optimal approach to developing transformative therapeutics across cancer indications. The company was founded in 2021 by Katrin Rupalla. The CEO is Peter Schiemann. | Corporate Officer/Principal | 01.12.2021 | - |
Gründer | 01.12.2021 | - | |
Vorstandsvorsitzender | 01.12.2021 | - | |
The Cancer Drug Development Forum | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Katrin Rupalla
Ehemalige bekannte Positionen von Katrin Rupalla
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ZYVERSA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 05.01.2023 | 18.05.2023 |
Independent Dir/Board Member | 05.01.2023 | 18.05.2023 | |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Direktor/Vorstandsmitglied | 01.04.2021 | 15.08.2022 |
Vorsitzender | 15.08.2022 | 18.05.2023 | |
Independent Dir/Board Member | 01.04.2021 | 18.05.2023 | |
H. LUNDBECK A/S | Corporate Officer/Principal | 01.10.2019 | 01.12.2021 |
Iqure Pharma, Inc.
Iqure Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Iqure Pharma, Inc. is a biotech company that develops therapeutics for patients and physicians. The company is based in Wilmington, DE. The company was founded by Pawel Zolnierczyk, Henk de Wilde, Peter Schiemann, Anna Rzewuska. Pawel Zolnierczyk has been the CEO since incorporation. | Direktor/Vorstandsmitglied | 01.06.2020 | 01.04.2021 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.05.2012 | 01.07.2019 |
░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░ | - | - |
Ausbildung von Katrin Rupalla
Philipps University of Marburg | Doctorate Degree |
Jones International University | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 7 |
Schweiz | 3 |
Vereinigtes Königreich | 3 |
Operativ
Director/Board Member | 6 |
Corporate Officer/Principal | 4 |
Independent Dir/Board Member | 3 |
Sektoral
Health Technology | 9 |
Consumer Services | 3 |
Miscellaneous | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
4D PHARMA PLC | Health Technology |
H. LUNDBECK A/S | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ZYVERSA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 7 |
---|---|
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Health Technology |
Ambrx, Inc.
Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Bristol-Myers Squibb Holdings Ltd.
Bristol-Myers Squibb Holdings Ltd. MiscellaneousMiscellaneous Part of Bristol Myers Squibb Co., Bristol-Myers Squibb Holdings Ltd. is a holding British company. The company is based in Uxbridge, UK. | Miscellaneous |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
Ymmunobio AG
Ymmunobio AG BiotechnologyHealth Technology Ymmunobio AG is a Swiss preclinical stage oncology biotech company that develops innovative treatments for cancer patients through new classes of antibodies. The company is based in Riehen, Switzerland. The company focuses on high unmet need indications in gastro-intestinal cancers, making extensive progress in developing first-in-class or novel class of antibodies that have the potential to overcome resistance of cancer patients to current available therapies. Ymmunobio's research is based on their deep understanding of immuno-oncology and precision cancer treatments, leveraging their profound knowledge of biologics while selecting the optimal approach to developing transformative therapeutics across cancer indications. The company was founded in 2021 by Katrin Rupalla. The CEO is Peter Schiemann. | Health Technology |
Iqure Pharma, Inc.
Iqure Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Iqure Pharma, Inc. is a biotech company that develops therapeutics for patients and physicians. The company is based in Wilmington, DE. The company was founded by Pawel Zolnierczyk, Henk de Wilde, Peter Schiemann, Anna Rzewuska. Pawel Zolnierczyk has been the CEO since incorporation. | Commercial Services |
The Cancer Drug Development Forum |
- Börse
- Insiders
- Katrin Rupalla
- Erfahrung